Abstract Number: 564 • 2019 ACR/ARP Annual Meeting
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…Abstract Number: 571 • 2019 ACR/ARP Annual Meeting
Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry
Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…Abstract Number: 581 • 2019 ACR/ARP Annual Meeting
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…Abstract Number: 619 • 2019 ACR/ARP Annual Meeting
Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory arthritis that predominantly affects the axial skeleton, but commonly affects peripheral joints as well. Peripheral joint involvement often…Abstract Number: 1512 • 2019 ACR/ARP Annual Meeting
Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results
Background/Purpose: Enteropathic spondylitis (eSpA) is younger brother of spondyloarthritis, and the retention rate of biological DMARD in eSpA was not yet clear. The objective of this study was to…Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…Abstract Number: 933 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…Abstract Number: 935 • 2019 ACR/ARP Annual Meeting
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…
- 1
- 2
- 3
- …
- 28
- Next Page »